文献速递呼吸道感染

克拉霉素用于社区获得性肺炎早期抗炎反应:ACCESS随机双盲安慰剂对照试验

Clarithromycin for early anti-inflammatory responses in community-acquired pneumonia in Greece (ACCESS): a randomised, double-blind, placebo-controlled trial.
PubMed 文献 · Lancet Respir Med · 2024-01-03

BACKGROUND: Addition of macrolide antibiotics to β-lactam antibiotics for the treatment of patients in hospital with community-acquired pneumonia is based on results from observational studies and meta-analyses rather than randomised clinical trials.…

要点

  • 住院社区获得性肺炎患者在β-内酰胺类基础上加用克拉霉素可显著提高第4天早期临床和炎症反应复合终点达标率。
  • 严重治疗中出现不良事件克拉霉素组43% vs 安慰剂组53%,差异无统计学意义,且无一例判定与治疗分配相关。

核心结论

  • 在标准治疗基础上加用克拉霉素可增强住院社区获得性肺炎患者的早期临床应答并减轻炎症负担,其获益机制与免疫应答改变相关。

研究设计与样本

  • ACCESS试验为3期前瞻性、双盲、随机对照试验,在希腊18个公立医院内科病房纳入278例住院社区获得性肺炎成人患者。
  • 患者按1:1计算机生成区组随机分配至标准治疗(含静脉第三代头孢菌素或静脉β-内酰胺加β-内酰胺酶抑制剂)联合口服克拉霉素500 mg每日两次或口服安慰剂,疗程7天。

主要发现

  • 克拉霉素组134例、安慰剂组133例纳入主要终点分析。
  • 无一例严重治疗中出现不良事件被判定与治疗分配相关。

临床怎么用

  • 对符合条件的住院社区获得性肺炎成人患者,可考虑在β-内酰胺类标准治疗基础上加用克拉霉素500 mg每日两次口服7天,以促进早期临床应答和炎症负担下降。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Addition of macrolide antibiotics to β-lactam antibiotics for the treatment of patients in hospital with community-acquired pneumonia is based on results from observational studies and meta-analyses rather than randomised clinical trials. We investigated if addition of the macrolide clarithromycin to treatment with a β-lactam antibiotic in this population could improve early clinical response-the new regulatory endpoint for community-acquired pneumonia-and explored the possible contribution of modulation of the inflammatory host response to that outcome. METHODS: The ACCESS trial was a phase 3 prospective, double-blind, randomised controlled trial, in which adults in hospital with community-acquired pneumonia who had systemic inflammatory response syndrome, Sequential Organ Failure Assessment (SOFA) score of 2 or more, and procalcitonin 0·25 ng/mL or more were enrolled in 18 internal medicine departments of public Greek hospitals. Patients were randomly assigned (1:1) by computer-generated block randomisation to standard of care medication (including intravenous administration of a third-generation cephalosporin or intravenous administration of β-lactam plus β-lactamase inhibitor combination) plus either oral placebo or oral clarithromycin 500 mg twice daily for 7 days. Investigators, staff, and patients were masked to group allocation. The primary composite endpoint required that patients fulfilled both of the following conditions after 72 hours (ie, day 4 of treatment): (1) decrease in respiratory symptom severity score of 50% or more as an indicator of early clinical response and (2) decrease in SOFA score of at least 30% or favourable procalcitonin kinetics (defined as ≥80% decrease from baseline or procalcitonin <0·25 ng/mL), or both, as an indicator of early inflammatory response. Participants who were randomly assigned and received allocated treatment were included in the primary analysis population. This trial is complete and is registered with the EU Clinical Trials Register (2020-004452-15) and ClinicalTrials.gov (NCT04724044). FINDINGS: Patients were enrolled between Jan 25, 2021, and April 11, 2023, and 278 individuals were randomly allocated to receive standard of care in combination with either clarithromycin (n=139) or placebo (n=139). 134 patients in the clarithromycin group (five withdrew consent) and 133 patients in the placebo group (six withdrew consent) were included in the analysis of the primary endpoint. The primary endpoint was met in 91 (68%) patients in the clarithromycin group and 51 (38%) patients in the placebo group (difference 29·6% [95% CI 17·7-40·3]; odds ratio [OR] 3·40 [95% CI 2·06-5·63]; p<0·0001). Serious treatment-emergent adverse events (TEAEs) occurred in 58 (43%) patients in the clarithromycin group and 70 (53%) patients in the placebo group (difference 9·4% [95% CI -2·6 to 20·9]; OR 0·67 [95% CI 0·42 to 1·11]; p=0·14). None of the serious TEAEs was judged to be related to treatment assignment. INTERPRETATION: Addition of clarithromycin to standard of care enhances early clinical response and attenuates the inflammatory burden of community-acquired pneumonia. The mechanism of benefit is associated with changes in the immune response. These findings suggest the importance of adding clarithromycin to β-lactams for treatment of patients in hospital with community-acquired pneumonia to achieve early clinical response and early decrease of the inflammatory burden. FUNDING: Hellenic Institute for the Study of Sepsis and Abbott Products Operations.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Giamarellos-Bourboulis, Siampanos, Bolanou, et al. Clarithromycin for early anti-inflammatory responses in community-acquired pneumonia in Greece (ACCESS): a randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2024. PMID: 38184008. doi:10.1016/S2213-2600(23)00412-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。